0000000000550470

AUTHOR

Samia Bensalem

showing 2 related works from this author

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.

2017

BACKGROUND Degludec is an ultralong-Acting, once-daily basal insulin that is approved for use in adults, adolescents, and children with diabetes. Previous open-label studies have shown lower day-To-day variability in the glucose-lowering effect and lower rates of hypoglycemia among patients who received degludec than among those who received basal insulin glargine. However, data are lacking on the cardiovascular safety of degludec. METHODS We randomly assigned 7637 patients with type 2 diabetes to receive either insulin degludec (3818 patients) or insulin glargine U100 (3819 patients) once daily between dinner and bedtime in a double-blind, treat-To-Target, event-driven cardiovascular outco…

Insulin degludecBlood GlucoseMalemedicine.medical_treatmentDEVOTE Study GroupInsulin GlargineType 2 diabetesKaplan-Meier Estimate030204 cardiovascular system & hematologylaw.inventiondiabetes ; insulin0302 clinical medicineRandomized controlled triallawCardiovascular DiseaseGLUCOSE CONTROL11 Medical and Health SciencesRISKCOMPLICATIONSOUTCOMESIncidenceGeneral MedicineMiddle AgedInsulin Long-ActingVARIABILITYCardiovascular Diseasesdiabetes mellitusFemaleLife Sciences & BiomedicineHumanmedicine.drugmedicine.medical_specialty030209 endocrinology & metabolismAged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus Type 2; Double-Blind Method; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Insulin Glargine; Insulin Long-Acting; Kaplan-Meier Estimate; Male; Middle Aged; Medicine (all)HypoglycemiaBedtimeArticleEVENTS03 medical and health sciencesHYPOGLYCEMIAMedicine General & InternalDouble-Blind MethodInternal medicineDiabetes mellitusGeneral & Internal MedicinemedicineHumansHypoglycemic AgentsIntensive care medicineMETAANALYSISAgedScience & TechnologyHypoglycemic AgentInsulin glarginebusiness.industryInsulinmedicine.diseaseDiabetes Mellitus Type 2businessBASAL INSULIN
researchProduct

Mechanism of the palladium-catalysed electrosynthesis of diethyl carbonate from carbon monoxide and ethanol

2004

Abstract A mechanism is proposed for the PdBr2(PPh3)2-catalysed electrosynthesis of diethyl carbonate from carbon monoxide and ethanol, proceeding at room temperature and atmospheric CO pressure. The mechanism is investigated by cyclic voltammetry and 31P NMR spectroscopy. The active Pd0 complex able to coordinate CO is generated by the chemical reduction of PdBr2(PPh3)2 by EtO– ions generated from EtOH at the cathode. After reaction of EtO– ions with Pd0(PPh3)2(CO), the ensuing anionic complex [(PPh3)2Pd0–COOEt]– is oxidized at the anode in a key step leading to BrPdII–COOEt(PPh3)2. A nucleophilic attack of ethoxide on the latter generates diethyl carbonate and the Pd0 complex active in th…

Reaction mechanismGeneral Chemical EngineeringInorganic chemistryDiethyl carbonatechemistry.chemical_elementGeneral ChemistryElectrosynthesisCatalysischemistry.chemical_compoundchemistryCyclic voltammetryCarbonylationCarbon monoxidePalladiumComptes Rendus Chimie
researchProduct